|Bid||4.14 x 100|
|Ask||5.68 x 200|
|Day's range||4.35 - 4.59|
|52-week range||3.75 - 19.47|
|PE ratio (TTM)||N/A|
|Earnings date||3 May 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||8.00|
NewLink Genetics Corporation today presented a poster entitled “Indoximod modulates AhR-driven transcription of genes that control immune function” in the Immunomodulatory Agents and Interventions session at the American Association for Cancer Research 2018 Annual Meeting in Chicago.
NewLink toppled Monday after it scrapped a late-stage study of its immuno-oncology drug in combination with drugs from Merck and Bristol.
NewLink Genetics Corp. shares fell as much as 15% in premarket trade Monday after the company said it won't proceed as planned with a late-stage trial of its indoximod for advanced melanoma. The company ...
Shares of NewLink Genetics Corp. (NLNT) plunged about 42.6% following the news of the failure of Incyte and Merck's phase III combination study for metastatic melanoma.
Incyte's (INCY) epacadostat in combination with Merck's Keytruda fails to meet primary endpoint of PFS in a phase III melanoma study.
NewLink Genetics Corp. plans to review its clinical programs after the failure of a similar drug in a Merck and Incyte clinical trial. NewLink noted that the mechanism of its drug, an IDO pathway inhibitor ...
NewLink Genetics Corp. shares plummeted 39.2% in premarket trade Friday after Merck and Incyte Corp. said their trial testing a combination including a type of cancer drug called an IDO inhibitor had failed. ...
The Ames, Iowa-based company said it had a loss of 37 cents per share. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss ...
Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of NewLink Genetics Corporation into potential breaches of fiduciary duty by the Company’s Board of Directors .
The Ames, Iowa-based company said it had a loss of 69 cents per share. The results exceeded Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for ...
NewLink Genetics Corporation , a late-stage biopharmaceutical company, today announced that it intends to offer and sell, subject to market conditions, up to $50,000,000 of shares of its common stock in an underwritten public offering.
ASCO's abstract drop reveals the progress being made in attacking cancer and, inevitably, moves stocks both large and small.